A Global Clinical-Stage Biotechnology Company That Seeks To Develop Novel And Best-In-Class Gene Therapy Medicines To Improve The Lives Of Patients Across Multiple Disease Areas, Today Announced That It Has Dosed The First Patient In A Phase 1 Clinical Trial Of Its Lead Gene Therapy Program, Ft-001, For The Treatment Of Leber Congenital Amaurosis-2, A Severe Inherited Retinal Disease Related To A Mutation In The Rpe65 Gene. Ft-001 Is Administered By A One-Time Injection Into The Subretinal Space Of The Eye That Delivers A Functional Copy Of The Human Rpe65 Gene To The Nuclei Of The Patient
